Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Interest & Investment Income of $114.8 million for Q1 2026, down 2.63% year-over-year from $117.9 million in Q1 2025, and down 5.82% quarter-over-quarter from $121.9 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Interest & Investment Income (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $114.8 million for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 2.63% year-over-year to $114.8 million; the TTM figure through Mar 2026 stood at $484.8 million (down 9.35% YoY), while the FY2025 annual figure was $490.9 million, down 17.92% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $114.8 million, down from $121.9 million in the prior quarter.
- The five-year high for Interest & Investment Income was $181.2 million in Q1 2024, with the low at $1.6 million in Q1 2022.
- The 5-year median for Interest & Investment Income is $122.6 million (2023), against an average of $115.3 million.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income jumped 7562.5% in 2023, then plunged 34.93% in 2025.
- Vertex Pharmaceuticals' Interest & Investment Income stood at $86.0 million in 2022, then jumped by 108.72% to $179.5 million in 2023, then dropped by 28.58% to $128.2 million in 2024, then declined by 4.91% to $121.9 million in 2025, then retreated by 5.82% to $114.8 million in 2026.
- Business Quant data shows VRTX's Interest & Investment Income at $114.8 million in Q1 2026, $121.9 million in Q4 2025, and $125.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 48.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 35.58 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 27.90 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 5.13 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 28.14 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 36.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 120.60 Mn |
| Mar 31, 2026 | 114.80 Mn |
| Dec 31, 2025 | 121.90 Mn |
| Sep 30, 2025 | 125.70 Mn |
| Jun 30, 2025 | 122.40 Mn |
| Mar 31, 2025 | 117.90 Mn |
| Dec 31, 2024 | 128.20 Mn |
| Sep 30, 2024 | 132.20 Mn |
| Jun 30, 2024 | 156.50 Mn |
| Mar 31, 2024 | 181.20 Mn |
| Dec 31, 2023 | 179.50 Mn |
| Sep 30, 2023 | 167.90 Mn |
| Jun 30, 2023 | 144.70 Mn |
| Mar 31, 2023 | 122.60 Mn |
| Dec 31, 2022 | 86.00 Mn |
| Sep 30, 2022 | 46.20 Mn |
| Jun 30, 2022 | 10.80 Mn |
| Mar 31, 2022 | 1.60 Mn |
| Dec 31, 2021 | 1.20 Mn |
| Sep 30, 2021 | 1.10 Mn |